EAM
ACAD icon

Eventide Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Eventide Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-575,541
Closed -$12.3M – 269
2025
Q3 		$12.3M Sell
575,541
-152,896
-21% -$3.62M 0.2% 121
2025
Q2 		$15.7M Sell
728,437
-124,408
-15% -$2.31M 0.28% 107
2025
Q1 		$14.2M Hold
852,845
– – 0.28% 105
2024
Q4 		$15.6M Buy
852,845
+275,345
+48% +$4.44M 0.29% 109
2024
Q3 		$8.88M Buy
+577,500
New +$9.63M 0.15% 125
2024
Q1 		– Sell
-809,391
Closed -$25.3M – 158
2023
Q4 		$25.3M Buy
+809,391
New +$19.3M 0.41% 75
2018
Q3 		– Sell
-113,600
Closed -$1.74M – 146
2018
Q2 		$1.74M Hold
113,600
– – 0.07% 118
2018
Q1 		$2.55M Sell
113,600
-221,100
-66% -$6.12M 0.12% 103
2017
Q4 		$10.1M Hold
334,700
– – 0.53% 61
2017
Q3 		$12.6M Hold
334,700
– – 0.71% 53
2017
Q2 		$9.34M Hold
334,700
– – 0.58% 51
2017
Q1 		$11.5M Hold
334,700
– – 0.76% 47
2016
Q4 		$9.65M Hold
334,700
– – 0.63% 51
2016
Q3 		$10.6M Hold
334,700
– – 0.65% 49
2016
Q2 		$10.9M Hold
334,700
– – 0.66% 52
2016
Q1 		$9.36M Hold
334,700
– – 0.52% 56
2015
Q4 		$11.9M Buy
334,700
+8,000
+2% +$282K 0.6% 55
2015
Q3 		$10.8M Buy
326,700
+55,600
+21% +$2.31M 0.63% 49
2015
Q2 		$11.4M Hold
271,100
– – 0.61% 54
2015
Q1 		$8.84M Sell
271,100
-152,100
-36% -$5.23M 0.66% 57
2014
Q4 		$13.4M Hold
423,200
– – 1.47% 24
2014
Q3 		$10.5M Hold
423,200
– – 1.46% 27
2014
Q2 		$9.56M Buy
423,200
+229,700
+119% +$4.8M 1.3% 33
2014
Q1 		$4.71M Buy
193,500
+18,100
+10% +$458K 0.73% 55
2013
Q4 		$4.38M Buy
+175,400
New +$4.14M 1.35% 40

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Eventide Asset Management's ACAD Position: Q4 2025 in Review

Eventide Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 575,541 shares — an estimated $12.3M sold.

Eventide Asset Management first reported a position in ACAD in Q4 2013 and held it in 25 quarters. The position peaked at $25.3M in Q4 2023. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Eventide Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Eventide Asset Management sold 575,541 Acadia Pharmaceuticals shares in Q4 2025, an estimated $12.3M.
  • Eventide Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 25 quarters.
  • Eventide Asset Management's Acadia Pharmaceuticals position peaked at $25.3M in Q4 2023.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.